


PHARMACEUTICAL 2022

Theriva Biologics Inc. Rank 67 of 466







PHARMACEUTICAL 2022



Theriva Biologics Inc. Rank 67 of 466

The relative strengths and weaknesses of Theriva Biologics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theriva Biologics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 69% points. The greatest weakness of Theriva Biologics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 261%, being 183% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	68,858
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,554
Liabilities, Non-Current	1,403
Other Assets	1,406
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	6.0
Other Revenues	0
Property and Equipment	101
Research and Development	7,800
Selling, General and Administrative Expense	6,474

Output Variable	Value in 1000 USD
Assets	70,365
Liabilities	4,957
Expenses	14,274
Revenues	0
Stockholders Equity	65,408
Net Income	-14,268
Comprehensive Net Income	-14,268
Economic Capital Ratio	261%

